The Anti-VEGF Antibody Bevacizumab Potently Reduces the Growth Rate of High-Risk Neuroblastoma Xenografts

Lova Segerström(Karolinska Institutet), Faranak Azarbayjani(Uppsala University)
Pediatric Research
September 21, 2006
Cited by 96


Related Papers